Caris Diagnostics Announces Name Change of Parent Company to Caris Life Sciences, Inc.

Caris Diagnostics (Caris Dx) today announced that its parent company’s name will change to Caris Life Sciences, Inc., effective immediately. The new name reflects the Company’s successful evolution into a multi-faceted organization that is pioneering precision healthcare, leading to improved patient outcomes and lowered healthcare costs. Caris Life Sciences is focused on five key areas of personalized medicine: Anatomic Pathology, Molecular Profiling, Proprietary Blood-Based Diagnostics, Pharmaceutical Services, and Research and Development.

“The promise of precision healthcare is quickly becoming a reality, thanks in large part to the revolutionary advances in molecular science. Caris Life Sciences reflects our mission of providing quality products and services well beyond that of a traditional diagnostic company or laboratory,” said David D. Halbert, Chairman and CEO. “Our current advances in research and development, along with our expanded service offerings, are better conveyed by Caris Life Sciences. We are particularly excited about our emerging proprietary technologies that will be able to diagnose diseases in their earliest stages using simple blood tests.”

Caris Diagnostics, a division of Caris Life Sciences, will continue to provide academic-caliber anatomic pathology services, primarily in the fields of dermatology, gastroenterology, hematology, and oncology. A majority of the Company’s 60+ pathologists hold or have held faculty positions at leading academic institutions such as Johns Hopkins, Harvard, Cleveland Clinic, and UT Southwestern. With almost 700 years of collective experience, these pathologists have published over 1,500 peer-reviewed publications and more than 100 books and book chapters.

In addition, Caris Life Sciences will focus on expanding its Caris Target Now™ series of tests, innovative molecular profiling and evidence systems, that enable physicians to make more informed treatment decisions for their cancer patients. The Company will also be growing its presence as a leading partner to the biopharmaceutical industry in the areas of biomarker research and companion diagnostics. The Company will be increasing investments in research and development efforts, focusing on innovative and proprietary technologies that will create new opportunities for precision medicine. These revolutionary technologies will enable physicians to provide patients with more precise information and conduct effective medical interventions that have fewer side-effects at earlier stages of their disease.

In conjunction with the name change, Caris Life Sciences is launching a new website to provide patients, physicians, and partners with comprehensive information related to the Company’s endeavors and offerings. These efforts align the Caris Life Sciences brand with the Company’s mission — bringing better outcomes to patients today and advancing the frontier of what is possible tomorrow. The new website can be found at

About Inform Diagnostics (formerly Caris Diagnostics)

Inform Diagnostics specializes in the development and commercialization of the highest quality anatomic pathology services, primarily in the fields of dermatopathology, Hematology/Oncology, gastrointestinal pathology and urologic pathology. The company’s core team of more than 70 world-leading, academic-caliber specialists utilize state of the art pathology laboratories currently headquartered in Irving, TX and throughout the United States to serve more than 3,000 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Inform Diagnostics continuously improves diagnostic precision.


Adam McGill, Perry Street Communications, (214) 965-9955 or

Categories: Press